Skip to Content
Here’s what to ask a doctor about hereditary angioedema

Imiquimod topical Pregnancy and Breastfeeding Warnings

Imiquimod topical is also known as: Aldara, Zyclara

Imiquimod topical Pregnancy Warnings

Animal studies have revealed evidence of adverse fetal effects at oral doses that also produced maternal toxicity. There are no controlled data in human pregnancy. AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use with caution; benefit should outweigh risk. -According to some authorities: Use is not recommended. AU TGA pregnancy category: B1 US FDA pregnancy category: C

See references

Imiquimod topical Breastfeeding Warnings

Caution is recommended. -According to some authorities: Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Unknown

No adverse effects were demonstrated in animal studies with rats treated with this drug during gestation and lactation at doses up to 8 times the maximum human dose on a mg/m2 basis.

See references

References for pregnancy information

  1. "Product Information. Aldara (imiquimod topical)." 3M Pharmaceuticals, St. Paul, MN.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Zyclara (imiquimod topical)." Medicis Pharmaceutical Corporation, Scottsdale, AZ.

References for breastfeeding information

  1. "Product Information. Aldara (imiquimod topical)." 3M Pharmaceuticals, St. Paul, MN.
  2. "Product Information. Zyclara (imiquimod topical)." Medicis Pharmaceutical Corporation, Scottsdale, AZ.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cerner Multum, Inc. "Australian Product Information." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide